Khiron Life Sciences Corp., a vertically integrated cannabis company with core operations in Latin America and Europe, has entered into an agreement with Nimbus Health, a leading German distributor of medical cannabis products. Khiron branded EU GMP medical cannabis will soon be available in Germany for prescription by doctors and dispensation in pharmacies.
Tejinder Virk, President of Khiron Europe, commented, “This is a major milestone for our company. Following our recent entry into the United Kingdom, the expansion into Germany will greatly benefit patients who still suffer from inconsistent supply. Khiron is now well positioned to service this rapidly expanding market in Germany.”
The supply of EU GMP medical cannabis to Germany will be fully supported by the Company’s global medical education team, led by Dr. Maria Fernanda Arboleda, Khiron’s International Director for Medical Services. Dr. Arboleda is an Anesthesiologist, Pain and Palliative Care Physician. She completed a Spine-Regional Anesthesia Fellowship at the McGill University Health Center and a Post-Doctoral Research Fellow in Supportive Cancer Care and Medical Cannabis, at the Department of Oncology, McGill University, and at Santé Cannabis, a leading specialized cannabis clinic in Canada.
Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented: “Germany continues to be the European leader in medical cannabis, with other countries observing and adapting to the German regulatory model. The market is also differentiated with its large proportion of patient prescriptions fully reimbursed through insurance.”
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products.
